Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

Bibliography

• Pogacic V, Herrling P. List of drugs in development for neurodegenerative diseases: update June 2007. Neurodegenerative Dis 2007;4:443-86
   PubMed Web of Science ®Google Scholar
• Pogacic Kramp V, Herrling P. List of drugs in development for neurodegenerative diseases: update October 2011. Neurodegenerative Dis 2012; published online 30 December 2011; doi:10.1159/000335520
   PubMed Web of Science ®Google Scholar
• Scatena R, Martorana GE, Bottoni P, An update on pharmacological approaches to neurodegenerative diseases. Expert Opin Investig Drugs 2007;16:59-72
   PubMed Web of Science ®Google Scholar
• Kwon MO, Herrling P. List of drugs in development for neurodegenerative diseases: update September 2005. Neurodegenerative Dis 2005;2:61-108
   PubMed Web of Science ®Google Scholar
• Stanzione P, Tropepi D. Drugs and clinical trials in neurodegenerative diseases. Ann Ist Super Sanita 2011;47:49-54
   PubMed Web of Science ®Google Scholar
• Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004;10:1055-63
   PubMed Web of Science ®Google Scholar
• Hampel H, Prvulovic D, Teipel S, The future of Alzheimer's disease: the next 10 years. Prog Neurobiol 2011;95:718-28
   PubMed Web of Science ®Google Scholar
• Tayeb HO, Yang HD, Price BH, Tarazi FI. Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther 2012;134:8-25
   PubMed Web of Science ®Google Scholar
• Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2007;9:387-98
   Google Scholar
• Fournier A, Oprisiu-Fournier R, Serot JM, Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev Neurother 2009;9:1413-31
   PubMed Web of Science ®Google Scholar
• Paris D, Bachmeier C, Patel N, Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier. Mol Med 2011;17:149-62
   PubMed Web of Science ®Google Scholar
• Kennelly S, Abdullah L, Kenny RA, Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients-an open-label trial. Int J Geriatr Psychiatry 2012;27:415-22
   PubMed Web of Science ®Google Scholar
• Seo JS, Baek IS, Leem YH, SK-PC-B70M alleviates neurologic symptoms in G93A-SOD1 amyotrophic lateral sclerosis mice. Brain Res 2011;1368:299-307
   PubMed Web of Science ®Google Scholar
• Bezprozvanny I. The rise and fall of dimebon. Drug News Perspect 2010;23(8):518-23
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Shill HA. Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs 2010;11:80-91
   PubMed Web of Science ®Google Scholar
• Naga KK, Geddes JW. Dimebon inhibits calcium-induced swelling of rat brain mitochondria but does not alter calcium retention or cytochrome C release. Neuromolecular Med 2011;13:31-6
   PubMed Web of Science ®Google Scholar
• Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011;221:555-63
   PubMed Web of Science ®Google Scholar
• Kawamata J, Shimohama S. Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J Alzheimer Dis 2011;24:95-109
   PubMed Web of Science ®Google Scholar
• Wallace TL, Porter RHP. Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol 2011;82:891-903
   PubMed Web of Science ®Google Scholar
• Prickaerts J, van Goethem NP, Chesworth R, EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 2012;62:1099-110
   PubMed Web of Science ®Google Scholar
• Hilt D, Safirstein B, Hassman D, EVP-6124: safety, tolerability and cognitive effects of a novel alpha7 nicotinic receptor agonist in Alzheimer's disease patients on stable donepezil or rivastigmine therapy. Alzheimer Dement 2009;5:e32
   Google Scholar
• Wallace TL, Callahan PM, Tehim A, RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 2011;336:242-53
   PubMed Web of Science ®Google Scholar
• Wallace TL, Chiu G, Dao H, R3487/MEM 3454, a novel nicotinic alpha 7 receptor partial agonist, improves attention and working memory performance in cynomolgus macaques. Biochem Pharmacol 2009;78:912
   Web of Science ®Google Scholar
• Hauser TA, Kucinski A, Jordan KG, TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 2009;78:803-12
   PubMed Web of Science ®Google Scholar
• Gatto GJ, Bohme GA, Caldwell WS, TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. CNS Drug Rev 2004;10:147-66
   PubMedGoogle Scholar
• Frohlich L, Ashwood T, Nilsson J, Eckerwall G. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study. J Alzheimer Dis 2011;24:363-74
   PubMed Web of Science ®Google Scholar
• Panza F, Frisardi V, Solfrizzi V, Interacting with gamma-secretase for treating Alzheimer's disease: from inhibition to modulation. Curr Med Chem 2011;18:5430-47
   PubMed Web of Science ®Google Scholar
• Petterson M, Kauffman GW, am Ende CW, Novel gamma-secretase modulators: a review of patents from 2008 to 2010. Expert Opin Ther Patents 2011;21:205-26
   PubMed Web of Science ®Google Scholar
• Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009;110:1129-34
   PubMed Web of Science ®Google Scholar
• Gillman KW, Starrett JE, Parker MF, Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable gamma-secretase inhibitor. ACS Med Chem Lett 2010;1:120-4
   PubMed Web of Science ®Google Scholar
• Albright C, Andreasen N, Minthon L, The gamma-secretase inhibitor BMS-708163 causes dose-dependent reductions in CSF Abeta40 levels in patients with mild-to-moderate Alzheimer's disease (AD). Alzheimer Dement 2011;7:S311
   Google Scholar
• Mitani Y, Yarimizu J, Saita K, Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 2012;32:2037-50
   PubMed Web of Science ®Google Scholar
• Cook JJ, Wildsmith KR, Gilberto DB, Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci 2010;30:6743-50
   PubMed Web of Science ®Google Scholar
• Shih I, Wang T. Notch signalling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82
   PubMed Web of Science ®Google Scholar
• Pasinetti G, Rosen Z, Grossman H. Nic5-15: a novel natural gamma-secretase inhibitor that attenuates brain beta-amyloid content and improves cognition. Alzheimer Dement 2009;5:e28
   Google Scholar
• Available from: www.qrpharma.com/presentation.html [Last accessed 15 March 2012]
   Google Scholar
• Rogers JT, Mikkilineni S, Cantuti-Castelvetri I, The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transm 2011;118:493-507
   PubMed Web of Science ®Google Scholar
• Green KN, Khashwji H, Estrada T, Laferla FM. ST101 induces a novel 17kDa APP cleavage that precludes Abeta generation in vivo. Ann Neurol 2011;69:831-44
   PubMed Web of Science ®Google Scholar
• Kenche VB, Barnham KJ. Alzheimer's disease & metals: therapeutic opportunities. Br J Pharmacol 2011;163:211-19
   PubMed Web of Science ®Google Scholar
• Crouch PJ, Savva MS, Hung LW, The Alzheimer's therapeutic PBT2 promotes amyloid beta-degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem 2011;119:220-30
   PubMed Web of Science ®Google Scholar
• Faux NG, Ritchie CW, Gunn A, PBT2 rapidly improves cognition in Alzheimer's disease: additional phase II analyses. J Alzheimer Dis 2010;20:509-16
   PubMed Web of Science ®Google Scholar
• Nguyen T, Hamby A, Massa SM. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005;102:11840-5
   PubMed Web of Science ®Google Scholar
• Fenili D, Brown M, Rappaport R, McLaurin J. Properties of scyllo–inositol as a therapeutic treatment of AD-like pathology. J Mol Med 2007;85:603-11
   PubMed Web of Science ®Google Scholar
• Fenili D, Weng Y, Aubert I, Sodium/myo-inositol transporters: substrate transport requirements and regional brain expression in the TgCRND8 mouse model of amyloid pathology. PLoS ONE 2011;6:e24032
   PubMedGoogle Scholar
• Salloway S, Sperling R, Keren R, A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011;77:1253-62
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Agro A, Bell J, PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:206-12
   PubMed Web of Science ®Google Scholar
• Srikanth V, Maczurek A, Phan T, Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011;32:763-77
   PubMed Web of Science ®Google Scholar
• Galasko DR, Van Dyck C, Sabbagh M, A randomized clinical trial of an inhibitor of RAGE-Abeta interactions in patients with mild to moderate AD. J Nutr Health Aging 2011;15:S9
   Google Scholar
• Available from: http://www.acimmune.com/content/?p=41 [Last accessed 17 February 2012]
   Google Scholar
• De Filippis D, Cipriano M, Esposito G, Are anti-angiogenic drugs useful in neurodegenerative disorders? CNS Neurol Disord Drug Targets 2010;9:807-12
   PubMed Web of Science ®Google Scholar
• Avramovich Y, Amit T, Youdim MBH. Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J Biol Chem 2002;277:31466-73
   PubMed Web of Science ®Google Scholar
• Ryu JK, McLarnon JG. Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-alpha in an animal model of inflamed Alzheimer's disease brain. Neurobiol Dis 2008;29:254-66
   PubMed Web of Science ®Google Scholar
• Alkam T, Nitta A, Mizoguchi H. Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res 2008;189:100-6
   PubMed Web of Science ®Google Scholar
• Kiaei M, Petri S, Kipiani K, Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26:2467-73
   PubMed Web of Science ®Google Scholar
• Fukushima T, Nakamura A, Iwakami N, T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice. Biochem Biophys Res Commun 2011;407:730-4
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Ago Y, Kitao T, A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology 2008;55:654-60
   PubMed Web of Science ®Google Scholar
• Esbenshade TA, Browman KE, Bitner RS, The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br J Pharmacol 2008;154:1166-81
   PubMed Web of Science ®Google Scholar
• Brioni JD, Esbenshade TA, Garrison TR, Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease. J Pharmacol Exp Ther 2011;336:38-46
   PubMed Web of Science ®Google Scholar
• Kuhne S, Wijtmans M, Lim HD, Several down, a few to go: histamine H3 receptor ligands making the final push towards the market? Expert Opin Investig Drugs 2011;20:1629-48
   PubMed Web of Science ®Google Scholar
• Gallant M, Aspiotis R, Day S, Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment. Bioorg Med Chem Lett 2010;20:6387-93
   PubMed Web of Science ®Google Scholar
• Halene TB, Siegel SJ. PDE inhibitors in psychiatry – future options for dementia, depression and schizophrenia? Drug Discov Today 2007;12:870-8
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang C, Lin H, Inhibition of phosphodiesterase-4 reverses memory deficits produced by Abeta25–35 or Abeta1–40 peptide in rats. Psychopharmacology 2010;212:181-91
   PubMed Web of Science ®Google Scholar
• Yang L, Calingasan NY, Lorenzo BJ, Beal MF. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol 2008;211:311-14
   PubMed Web of Science ®Google Scholar
• Li Y, Cheng Y, Huang Y, Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. J Neurosci 2011;31:172-83
   PubMed Web of Science ®Google Scholar
• Sengupta R, Sun T, Warrington NM, Rubin JB. Treating brain tumors with PDE4 inhibitors. Trends Pharmacol Sci 2011;32:337-44
   PubMed Web of Science ®Google Scholar
• Drott J, Desire L, Drouin D, Etazolate improves performance in a foraging and homing task in aged rats. Eur J Pharmacol 2010;634:95-100
   PubMed Web of Science ®Google Scholar
• Lichtenthaler SF. Alpha-secretase in Alzheimer's disease: molecular identity, regulation and therapeutic potential. J Neurochem 2011;116:10-21
   PubMed Web of Science ®Google Scholar
• Vellas B, Sol O, Snyder PJ, EHT0202 in Alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 2011;8:203-12
   PubMed Web of Science ®Google Scholar
• Dudas B, Hanin I, Rose M, Wulfert E. Protection against inflammatory neurodegeneration and glial cell death by 7beta-hydroxy epiandrosterone, a novel neurosteroid. Neurobiol Dis 2004;15:262-8
   PubMed Web of Science ®Google Scholar
• Youdim MB, Bar Am O, Yogev-Falach M, Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 2005;79:172-9
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Amit T, Weinreb O, Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J Alzheimer Dis 2010;21:361-71
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Bar-Am O, The neuroprotective mechanism of action of the multimodal drug ladostigil. Front Biosci 2008;13:5131-7
   PubMed Web of Science ®Google Scholar
• Gozes I. NAP (Davunetide) provides functional and structural neuroprotection. Curr Pharm Des 2011;17:1040-4
   PubMed Web of Science ®Google Scholar
• Shiryaev N, Jouroukhin Y, Giladi E, NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009;34:381-8
   PubMed Web of Science ®Google Scholar
• Fleming SM, Mulligan CK, Richter F, A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci 2011;46:597-606
   PubMed Web of Science ®Google Scholar
• Available from: www.allontherapeutics.com/product-development/davunetide/ [Last accessed 20 March 2012]
   Google Scholar
• Schirmer RH, Adler H, Pickhardt M. Mandelkow E. "Lest we forget you-methylene blue...". Neurobiol Aging 2011;32:e7-e16
   PubMedGoogle Scholar
• Mayer SC, Kreft AF, Harrison B, Discovery of begacestat, a notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease. Curr Med Chem 2011;18:5430-47
   PubMedGoogle Scholar
• Martone RL, Zhou H, Atchison K, Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther 2009;331:598-608
   PubMed Web of Science ®Google Scholar
• Schroeter S, Brighma E, Motter R, APP-selective gamma-secretase inhibitor ELND006 effects on brain parenchymal and vascular amyloid-beta in the PDAPP mouse model of Alzheimer's disease. Alzheimer Dement 2010;6:S546
   Google Scholar
• Brigham E, Quinn K, Motter R, Effects of single and multiple dose oral administration of ELND006, a novel APP-selective gamma-secretase inhibitor, on amyloid-beta concentrations in the brain and CSF of cynomolgus monkeys. Alzheimer Dement 2010;6:S546-7
   Google Scholar
• Hopkins CR. ACS chemical neuroscience molecule spotlight on ELND006: another gamma-secretase inhibitor fails in the clinic. ACS Chem Neurosci 2011;2:279-80
   PubMed Web of Science ®Google Scholar
• Oehlrich D, Berthelot DJ, Gijsen HJM. gamma-Secretase modulators as potential disease modifying anti-Alzheimer's drugs. J Med Chem 2011;54:669-98
   PubMed Web of Science ®Google Scholar
• Nagy C, Schuck E, Ishibashi A, E2012, a novel gamma-secretase modulator, decreases plasma amyloid-beta (Abeta) levels in humans. Alzheimer Dement 2010;6:S574
   Google Scholar
• Portelius E, Van Broeck B, Andreasson U, Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J Alzheimer Dis 2010;21:1005-12
   PubMed Web of Science ®Google Scholar
• Available from: http://www.envivopharma.com/news-item.php?id=28 [Last accessed 07 March 2012]
   Google Scholar
• Imbimbo BP, Giardino L, Sivilia S, CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J Alzheimer Dis 2010;20:159-73
   PubMed Web of Science ®Google Scholar
• Lanzillotta A, Sarnico I, Benarese M, The gamma-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci 2011;45:22-31
   PubMed Web of Science ®Google Scholar
• Balducci C, Mehdawy B, Mare L, The gamma-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J Alzheimer Dis 2011;24:799-816
   PubMed Web of Science ®Google Scholar
• Available from: http://gntpharma.com/web/bbs/board.php?bo_table=eb_0302&sca=AAD-2004 [Last accessed 17 February 2012]
   Google Scholar
• Shin JH, Lee YA, Lee JK, AAD-2004, a potent spin trapping molecule and microsomal prostaglandin E synthase-1 inhibitor, shows safety and efficacy in a mouse model of ALS. Nature Precedings 2010. Available from: http://hdl.handle.net/10101/npre.2010.5237.1 [Last accessed 17 February 2012]
   Google Scholar
• Ghosh AK, Brindisi M, Tang J. Developing beta-secretase inhibitors for treatment of Alzheimer's disease. J Neurochem 2012;120:71-83
   PubMed Web of Science ®Google Scholar
• Yu J, Koelsch G, Li A, In vivo efficacy of BACE-1 inhibitor CTS21166 (ASP1702) in rat CNS compartments. Alzheimer Dement 2009;5:P430-1
   Google Scholar
• Yu J, Koelsch G, Li A, Real-time microdialysis for Abeta inhibition and PK/PD analysis in a nonhuman primate model: in vivo efficacy of a BACE-1 inhibitor. Alzheimer Dement 2010;6:E73
   Google Scholar
• Aisen PS, Gauthier S, Ferris SH, Tramiprosate in mild-to-moderate Alzheimer's disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 2011;7:102-11
   PubMed Web of Science ®Google Scholar
• Gandhi NS, Mancera RL. Heparin/heparan sulphate-based drugs. Drug Discov Today 2010;15:1058-69
   PubMed Web of Science ®Google Scholar
• Available from: http://www.noscira.com/investigacion.cfm?mS=228&mSS=252 [Last accessed 07 March 2012]
   Google Scholar
• Galdeano C, Viayna E, Arroyo P, Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des 2010;16:2818-36
   PubMed Web of Science ®Google Scholar
• Snow AD, Cummings JA, Lake TP, P4-319: development of exebryl-1: a disease modifying small molecule therapeutic that causes a marked clearance of brain amyloid load and improved memory in transgenic mouse models of Alzheimer's disease. Alzheimer Dement 2006;2:S610
   Google Scholar
• Hu Q, Cam J, Lake T, Identification of Exebryl-1® and other novel small molecules as tau protein aggregation inhibitors. Alzheimer Dement 2011;7:S481
   Google Scholar
• Snow A, Cummings J, Lake T, Exebryl-1: a novel small molecule currently in human clinical trials as a disease-modifying drug for the treatment of Alzheimer's disease. Alzheimer Dement 2009;5:P418
   Google Scholar
• Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008;104:1433-9
   PubMed Web of Science ®Google Scholar
• Dominguez JM, Fuertes A, Orozco L, Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem 2012;287:893-904
   PubMed Web of Science ®Google Scholar
• Bolos M, Fernandez S, Torres-Aleman I. Oral administration of a GSK3 inhibitor increases brain insulin-like growth factor I levels. J Biol Chem 2010;285:17693-700
   PubMed Web of Science ®Google Scholar
• Madsen K, Neumann WJ, Holst K, Cerebral serotonin 4 receptors and amyloid-beta in early Alzheimer's disease. J Alzheimers Dis 2011;26:457-66
   PubMed Web of Science ®Google Scholar
• Lezoualc'h F. 5-HT4 receptor and Alzheimer's disease: the amyloid connection. Exp Neurol 2007;205:325-9
   PubMed Web of Science ®Google Scholar
• Shen F, Smith JA, Chang R, 5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology 2011;61:69-79
   PubMed Web of Science ®Google Scholar
• Available from: http://www.raqualia.com/product/5-ht4.html [Last accessed 20 February 2012]
   Google Scholar
• Buchholz M, Hamann A, Aust S, Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement. J Med Chem 2009;52:7069-80
   PubMed Web of Science ®Google Scholar
• Schilling S, Zeitschel U, Hoffmann T, Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease–like pathology. Nat Med 2008;14:1106-11
   PubMed Web of Science ®Google Scholar
• Alexandru A, Jagla W, Graubner S, Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Abeta is induced by pyroglutamate–Abeta formation. J Neurosci 2011;31:12790-801
   PubMed Web of Science ®Google Scholar
• Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease. Therapeutic implications. CNS Drugs 2008;22:1-14
   PubMed Web of Science ®Google Scholar
• Yamanaka M, Kurzwelly D, Reyes E, Heneka M. PPAR gamma/RXR induced and CD36-mediated Abeta phagocytosis results in cognitive improvement in APP/PS1 mice. Alzheimer Dement 2011;7:S401
   Google Scholar
• Available from: http://www.transitiontherapeutics.com/media/news.php [Last accessed 20 February 2012]
   Google Scholar
• Maurice T, Su TP. The pharmacology of sigma-1 receptors. Pharmacol Ther 2009;124:195-206
   PubMed Web of Science ®Google Scholar
• Su TP, Hyashi T, Maurice T, The sigma-1 receptor chaperone as an inter-organelle signaling modulator. Trends Pharmacol Sci 2010;31:557-66
   PubMed Web of Science ®Google Scholar
• Marrazzo A, Caraci F, Salinaro ET, Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity. Neuroreport 2005;16:1223-6
   PubMed Web of Science ®Google Scholar
• Villard V, Espallergues J, Keller E, Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (tau1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol 2011;25:1101-17
   PubMed Web of Science ®Google Scholar
• Available from: www.anavex.com/publications.html [Last accessed 20 March 2012]
   Google Scholar
• Luo W, Rodina A, Chiosis G. Heat shock protein 90: translation from cancer to Alzheimer's disease treatment? BMC Neurosci 2008;9:S7
   PubMedGoogle Scholar
• Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 2009;17:2225-35
   PubMed Web of Science ®Google Scholar
• Wang L, Xie C, Greggio E, The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 2008;28:3384-91
   PubMed Web of Science ®Google Scholar
• Dietz KC, Casaccia P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res 2010;62:11-17
   PubMed Web of Science ®Google Scholar
• Chuang D, Leng Y, Marinova Z, Multiple roles of HDAC inhibition in neurodegenerative conditions. Trend Neurosci 2009;32:591-601
   PubMed Web of Science ®Google Scholar
• Patzke H, Albayya FP, Besterman JM, Development of the novel histone deacetylase inhibitor EVP-0334 for CNS indications. 2008. p. 831. 21/I12
   Google Scholar
• Leventhal L, Tran A, Gallager I, The histone deacetylase inhibitor EVP-0334 is pro-cognitive in mice. 2008. p. 831. 20/I11
   Google Scholar
• Lynch G. Memory enhancement: the search for mechanism-based drugs. Nat Neurosci 2002;5:1035-8
   PubMed Web of Science ®Google Scholar
• Lauterborn JC, Pineda E, Chen LY, Ampakines cause sustained increases in brain-derived neurotrophic factor signaling at excitatory synapses without changes in AMPA receptor subunit expression. Neuroscience 2009;159:283-95
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Schapira AHV. Etiopathogenesis and treatment of Parkinson's disease. Curr Top Med Chem 2009;9:860-8
   PubMed Web of Science ®Google Scholar
• Meissner WG, Frasier M, Gasser T, Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011;10:377-93
   PubMed Web of Science ®Google Scholar
• Szabo N, Kincses ZT, Vecsei L. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. Expert Opin Drug Metab Toxicol 2011;7:441-55
   PubMed Web of Science ®Google Scholar
• Jenner P, Mori A, Hauser R, Adenosine, adenosine A2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 2009;15:406-13
   PubMed Web of Science ®Google Scholar
• Armentero MT, Pinna A, Ferre S, Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther 2011;132:280-99
   PubMed Web of Science ®Google Scholar
• Park A, Stacy M. Istradefylline for the treatment of Parkinson's disease. Expert Opin Pharmacother 2012;13:111-14
   PubMed Web of Science ®Google Scholar
• Muller CE, Jacobson KA. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta 2011;1808:1290-308
   PubMed Web of Science ®Google Scholar
• Hodgson RA, Bertorelli R, Varty GB, Characterization of the potent and highly selective A2A receptor antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther 2009;330:294-303
   PubMed Web of Science ®Google Scholar
• Hauser RA, Cantillon M, Pourcher E, Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011;10:221-9
   PubMed Web of Science ®Google Scholar
• Schapira AHV. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. Neurology 2009;72:S44-50
   PubMed Web of Science ®Google Scholar
• Jones CA, Johnston LC, Jackson MJ, An in vivo pharmacological evaluation of pardoprunox (SLV308) - a novel combined dopamine D2/D3 receptor partial agonist and 5-HT1A receptor agonist with efficacy in experimental models of Parkinson's disease. Eur Neuropsychopharmacol 2010;20:582-93
   PubMed Web of Science ®Google Scholar
• Sampaio C, Bronzova J, Hauser RA, Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov Disord 2011;26:1464-76
   PubMed Web of Science ®Google Scholar
• Sian-Hulsmann J, Mandel S, Youdim MBH, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 2011;118:939-57
   PubMed Web of Science ®Google Scholar
• Molina-Holgado F, Gaeta A, Francis PT, Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J Neurochem 2008;105:2466-76
   PubMed Web of Science ®Google Scholar
• Dexter DT, Statton SA, Whitmore C, Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm 2011;118:223-31
   PubMed Web of Science ®Google Scholar
• Velasco-Sanchez D, Aracil A, Montero R, Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 2011;10:1-8
   PubMed Web of Science ®Google Scholar
• Caccia C, Maj R, Calabresi M, Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67:S18-23
   PubMed Web of Science ®Google Scholar
• Gregoire L, Roach A, Di Paolo T. Safinamide reduces levodopa-induced dyskinesia in MPTP lesioned primates while prolonging anti-parkinsonian efficacy. Mov Disord 2010;25:S411-12
   Web of Science ®Google Scholar
• Anand R, Borgohain R, Bhatt M, Long-term efficacy of safinamide as add-on to levodopa in Parkinson's disease (PD) using an ‘ON' and ‘ON-OFF' treatment analysis. Parkinsonism Relat Disord 2012;18:S132
   PubMedGoogle Scholar
• Borgohain R, Mehta NA, Bajenaru OA, Effect of safinamide on depressive symptoms in patients with mid-late stage Parkinson's disease. Mov Disord 2010;25:S291
   Web of Science ®Google Scholar
• Anand R, Borgohain R, Stocchi F, First 2-year, placebo-controlled study in Parkinson's disease patients with motor fluctuations indicates safinamide may benefit patients with more severe dyskinesia. Parkinsonism Relat Disord 2012;18:S132-3
   PubMedGoogle Scholar
• Black KJ, Koller JM, Campbell MC, Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci 2010;30:16284-92
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Papapetropoulos S, Vandenhende F, An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin Neuropharmacol 2010;33:55-60
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xia Z, Hua Y, Role of glial cell derived neurotrophic factor in the protective effect of smilagenin on rat mesencephalic dopaminergic neurons damaged by MPP+. FEBS Lett 2008;582:956-60
   PubMed Web of Science ®Google Scholar
• Visanji NP, Orsi A, Johnston TH, PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J 2008;22:2488-97
   PubMed Web of Science ®Google Scholar
• Available from: http://www.phytopharm.co.uk/index.php?option= com_content&view=article&id=51& Itemid=37 [Last accessed 20 March 2012]
   Google Scholar
• Hu Y, Wang Z, Zhang R, Regulation of M1-receptor mRNA stability by smilagenin and its significance in improving memory of aged rats. Neurobiol Aging 2010;31:1010-19
   PubMed Web of Science ®Google Scholar
• Hadjiconstantinou M, Neff NH. GM1 ganglioside: in vivo and in vitro trophic actions on central neurotransmitter systems. J Neurochem 1998;70:1335-45
   PubMed Web of Science ®Google Scholar
• Wu G, Lu Z, Kulkarni N, Mice lacking major brain gangliosides develop parkinsonism. Neurochem Res 2011;36:1706-14
   PubMed Web of Science ®Google Scholar
• Schneider JS, Sendek S, Daskalakis C, Cambi F. GM1 ganglioside in Parkinson's disease: results of a five year open study. J Neurol Sci 2010;292:45-51
   PubMed Web of Science ®Google Scholar
• Available from: http://eng.skbp.com/index.asp [Last accessed 19 February 2012]
   Google Scholar
• Kincses ZT, Vecsei L. Pharmacological therapy in Parkinson's disease: focus on neuroprotection. CNS Neurosci Ther 2011;17:345-67
   PubMed Web of Science ®Google Scholar
• Szabo N, Kincses ZT, Toldi J, Vecsei L. Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach. J Neurol Sci 2011;310:256-60
   PubMed Web of Science ®Google Scholar
• Glicksman MA. The preclinical discovery of amyotrophic lateral sclerosis drugs. Expert Opin Drug Discov 2011;6:1127-38
   PubMed Web of Science ®Google Scholar
• Habib AA, Mitsumoto H. Emerging drugs for amyotrophic lateral sclerosis. Expert Opin Emerg Drugs 2011;16:537-58
   PubMed Web of Science ®Google Scholar
• Bordet T, Berna P, Abitbol J, Pruss RM. Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound. Pharmaceuticals 2010;3:345-68
   Google Scholar
• Duffy LM, Chapman AL, Shaw PJ, Grierson AJ. The role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2011;37:336-52
   PubMed Web of Science ®Google Scholar
• Sunyach C, Michaud M, Arnoux T, Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology 2012;62:2346-53
   PubMed Web of Science ®Google Scholar
• Phukan J. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs 2010;13:482-96
   PubMed Web of Science ®Google Scholar
• Kieran D, Kalmar B, Dick JR, Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402-5
   PubMed Web of Science ®Google Scholar
• Kalmar B, Novoselov S, Gray A, Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem 2008;107:339-50
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Simpson E, Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 2008;38:837-44
   PubMed Web of Science ®Google Scholar
• Gribkoff VK, Bozik ME. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther 2008;14:215-26
   PubMed Web of Science ®Google Scholar
• Alavian KN, Dworetzky SI, Bonanni L, Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res 2012;1446:1-11
   PubMed Web of Science ®Google Scholar
• Cudkowicz M, Bozik ME, Ingersoll EW, The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 2011;17:1652-6
   PubMed Web of Science ®Google Scholar
• Ito H, Wate R, Zhang J, Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 2008;213:448-55
   PubMed Web of Science ®Google Scholar
• Orrell RW. AEOL-10150 (Aeolus). Curr Opin Investig Drugs 2006;7:70-80
   PubMed Web of Science ®Google Scholar
• Crow JP, Calingasan NY, Chen J, Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 2005;58:258-65
   PubMed Web of Science ®Google Scholar
• Batinic-Haberle I, Spasojevic I, Tse HM, Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids 2012;42:95-113
   PubMed Web of Science ®Google Scholar
• Hersch SM, Rosas HD. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics 2008;5:226-36
   PubMed Web of Science ®Google Scholar
• Stack EC, Ferrante RJ. Huntington's disease: progress and potential in the field. Expert Opin Investig Drugs 2007;16:1933-53
   PubMed Web of Science ®Google Scholar
• Murck H, Manku M. Ethyl-EPA in Huntington disease – potentially relevant mechanism of action. Brain Res Bull 2007;72:159-64
   PubMed Web of Science ®Google Scholar
• Puri BK, Leavitt BR, Hayden MR, Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005;65:286-92
   PubMed Web of Science ®Google Scholar
• Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008;65:1582-9
   PubMed Web of Science ®Google Scholar
• Pallos J, Bodai L, Lukacsovich T, Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a drosophila model of Huntington's disease. Hum Mol Gen 2008;17:3767-75
   PubMed Web of Science ®Google Scholar
• Sadri-Vakili G, Cha JH. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr Alzheimer Res 2006;3:403-8
   PubMedGoogle Scholar
• Jeong H, Cohen DE, Cui L, Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med 2012;18:159-65
   Web of Science ®Google Scholar
• Jiang M, Wang J, Fu J, Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med 2012;18:153-8
   PubMed Web of Science ®Google Scholar
• Cen Y. Sirtuins inhibitors: the approach to affinity and selectivity. Biochim Biophys Acta 2010;1804:1635-44
   PubMed Web of Science ®Google Scholar
• Lavu S, Boss O, Elliott PJ, Lambert PD. Sirtuins - novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 2008;7:841-53
   PubMed Web of Science ®Google Scholar
• Gibrat C, Cicchetti F. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Prog Neuro Psychopharmacol Biol Psychol 2011;35:380-9
   PubMed Web of Science ®Google Scholar
• Williams P, Sorribas A, Howes MR. Natural products as a source of Alzheimer's drug leads. Nat Prod Rep 2011;28:48-77
   PubMed Web of Science ®Google Scholar
• Joyner PM, Cichewicz RH. Bringing natural products into the fold – exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases. Nat Prod Rep 2011;28:26-47
   PubMed Web of Science ®Google Scholar
• Georgiou NA, Garssen J, Witkamp RF. Pharma–nutrition interface: the gap is narrowing. Eur J Pharmacol 2011;651:1-8
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Youdim MBH, Carroll RT, Van der Schyf CJ. The emergence of designed multiple ligands for neurodegenerative disorders. Prog Neurobiol 2011;94:347-59
   PubMed Web of Science ®Google Scholar
• Morphy R, Rankovic Z. Designing multiple ligands – medicinal chemistry strategies and challenges. Curr Pharm Des 2009;15:587-600
   PubMed Web of Science ®Google Scholar
• Kitano H. A robustness-based approach to systems-oriented drug design. Nat Rev Drug Discov 2007;6:202-10
   PubMed Web of Science ®Google Scholar
• Cavalli A, Bolognesi ML, Minarini A, Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008;51:347-72
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Minarini A, Rosini M, From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease. Mini Rev Med Chem 2008;8:960-7
   PubMed Web of Science ®Google Scholar
• Leon R, Marco-Contelles J. A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-beta aggregation and Ca2+ dyshomeostasis. Curr Med Chem 2011;18:552-76
   PubMed Web of Science ®Google Scholar
• Bajda M, Guzior N, Ignasik M, Malawska B. Multi-target-directed ligands in Alzheimer's disease treatment. Curr Med Chem 2011;18:4949-75
   PubMed Web of Science ®Google Scholar
• Rampa A, Belluti F, Gobbi S, Bisi A. Hybrid-based multi-target ligands for the treatment of Alzheimer's disease. Curr Top Med Chem 2011;11:2716-30
   PubMed Web of Science ®Google Scholar
• Bolognesi ML, Cavalli A, Melchiorre C. Memoquin: a multi-target–directed ligand as an innovative therapeutic opportunity for Alzheimer's disease. Neurotherapeutics 2009;6:152-62
   PubMed Web of Science ®Google Scholar
• Pisani L, Catto M, Leonetti F, Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases. Curr Med Chem 2011;18:4568-87
   PubMed Web of Science ®Google Scholar
• Youdim MBH. M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. Parkinsonism Relat Disord 2012;18:S151-4
   PubMedGoogle Scholar
• Mandel S, Amit T, Bar-Am O, Youdim MBH. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol 2007;82:348-60
   PubMed Web of Science ®Google Scholar
• Zheng H, Youdim MB, Fridkin M. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem Biol 2010;5:603-10
   PubMed Web of Science ®Google Scholar
• Petzer JP, Castagnoli N, Schwarzschild MA, Dual-target–directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson's disease. Neurotherapeutics 2009;6:141-51
   PubMed Web of Science ®Google Scholar
• Becker RE, Greig NH, Giacobini E. Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J Alzheimer Dis 2008;15:303-25
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004;57:6-14
   PubMed Web of Science ®Google Scholar